Of the 21 patients who were screen failures, 10 failed because of HbA1c <6.0%, 7 failed because of reduced eGFR, 1 patient was also on a thiazide diuretic, 1 had started on an SGLT2 inhibitor, 1 was not on stable HF therapy (this patient had recently started taking sacubitril/valsartan), and 1 was not able to be randomized within 4 weeks as per protocol. The gene discussed is SLC5A2; the disease is hydrops fetalis.